Lysogene Appoints Chief Scientific Officer
Lysogene, a biotech company specialising in the treatment of central nervous system diseases, has appointed Kimberley S. Gannon chief scientific officer. Gannon joins the business from NeuroPhage Pharmaceuticals Inc., where she was senior vice president of preclinical research and development. Prior to this, she held several leadership positions at other companies, including vice president of research and development at CereMedix, and senior director of biology at EPIX (Predix) Pharmaceuticals. Her expertise spans preclinical pharmacology, translational medicine and nonclinical drug development.